nejm tirzepatide vs Semaglutide for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% weight loss at 72 wks • Semaglutide: −13.7% • Greater waist reduction In the SURMOUNT-5 phase 3b
Pay in 4 interest-free payments of $6.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
























